Investor Presentation
Released
Released
Announcement PDF
Company Announcement
IMAGION BIOSYSTEMS LIMITED
ASX: IBX
15 August 2024
Investor presentation
MELBOURNE – Imagion Biosystems (ASX:IBX), a company dedicated to improving healthcare
through the early detection of cancer, today advises it has released the attached investor
presentation which will be presented to investors at 10:00am (AEST) Thursday, 15 August 2024.
Highlights from the presentation include:
• Explanation of and reasons for the resolutions proposed for shareholder approval
• Update on our business plan and key milestones
• Q&A session with our leadership team
⎯ ENDS ⎯
About Imagion Biosystems
Imagion Biosystems is developing a new non-radioactive and precision diagnostic molecular
imaging technology. Combining biotechnology and nanotechnology, the Company aims to
detect cancer and other diseases earlier and with higher specificity than is currently possible.
For more information, visit https://imagionbiosystems.com/investor-hub/
Authorisation & Additional information
This announcement was authorised by the Board of Imagion Biosystems Limited.
Media & Investor Relations:
Email: info@imagionbio.com
AU: +61 3 9692 7222
MRI Imaging
Agents
for Cancer
Detection
A Breakthrough in
Molecular Magnetic
Resonance Imaging
Imagion Biosystems Limited
ASX:IBX
1
IBX Investor Deck
Copyright August 2024
| ImagionBiosystems.com
Imagion
Biosystems
Overview
Imagion
Biosystems
ASX:IBX
2
IBX Investor Deck
Copyright August 2024
| ImagionBiosystems.com
Imagion Biosystems Overview
A clinical stage biotechnology company developing
magnetic nanoparticle-based imaging and drug delivery
technologies
3
Molecular Imaging
Lead Product
Targeted nanoparticles have the potential to improve
cancer detection compared to conventional imaging
technologies by adding molecular specificity and without
using radioactivity.
A Phase 1 study for the detection of nodal metastases in
HER2+ Breast Cancer has been completed. IND for a
Phase 2 study in progress.
Drug Delivery
Strong Pipeline
Nanoparticles provide large surface area as carriers for
drugs or can be used as adjuvants in vaccines.
Imaging agents for primary tumor detection in Prostate
Cancer and Ovarian Cancer ready for
IND-enabling studies and clinical development.
IBX Investor Deck
Copyright August 2024
| ImagionBiosystems.com
An Unmet Need in Cancer Diagnosis
Screening
Conventional blood-based
tests, like PSA or CA125,
indicate risk of cancer but
are not diagnostic. Newer
methods like cfDNA or CTCs
improve screening but
require confirmation before
treatment.
4
IBX Investor Deck
Imaging
Biopsy
Current imaging
To confirm if a lesion is malignant, biopsies
methods can be used are taken which may be painful and cause
to identify a “region
patient complica-tions. Subsequent
of interest” or a
pathology assessment of the tissue
“suspicious lesion”
sample can take days. Obtaining tissue for
but can’t distinguish many types of cancer can be challenging,
between benign or
e.g. lung, pancreatic and
malignant lesions.
other deep body organ cancers.
A biopsy and pathology
assessment are required for
most cancers
Copyright August 2024
| ImagionBiosystems.com
Enabling Molecular Imaging
5
Conventional Imaging
MagSense®Imaging
Images provide anatomical context but are not
specific and can only identify a region of
interest.
Molecularly targeted imaging agents produce a
distinct image pattern indicating the presence of a
tumor.
IBX Investor Deck
Copyright August 2024
| ImagionBiosystems.com
How molecular
MRI works
MagSense® nanoparticles enable molecular
imaging by producing an identifiable change in
image contrast when cancer cells are present
• A targeting moiety (e.g. antibody or peptide)
directs the nanoparticles to the target tissue to ensure
cancer specific detection.
• When present in tissue, the magnetic nanoparticles create
hypointense (dark) contrast in T2 MRI scans.
• The hypointense contrast indicative of the presence of the
targeted MagSense® imaging agent can be differentiated
from normal tissue.
• The change in contrast improves radiological review when
combined with conventional imaging assess-ments, such as
abnormalities in tissue size and shape.
6
IBX Investor Deck
Node 1 shows a 27% change in signal intensity
Node 2 shows a 36% change in signal intensity
Copyright August 2024
| ImagionBiosystems.com
®
MagSense Molecular Imaging
MagSense® technology aims to transform how medical imaging can detect and diagnose cancer
7
MRI-based
Detection
Specific
Safer
Earlier
Detection
Platform
Technology
Imaging agents work with
exiting MRI systems widely
available in hospitals
around the globe.
Targeted imaging agents
provide molecular
confirmation of the presence
of cancer not just a visual
assessment of “suspicious” or
abnormal lesions.
Does not require use of
radioactivity and is a safe
and non-surgical solution
to detect cancer and
reduce the need for
investigative biopsies.
Would enable earlier detection
of solid tumors when small and
not easily visible by
conventional methods and/or
difficult and risky to biopsy.
Fits with existing
diagnostic protocols and
can be used for many
cancers as well as other
diseases.
IBX Investor Deck
Copyright August 2024
| ImagionBiosystems.com
®
MagSense
Use Cases
8
IBX Investor Deck
Copyright August 2024
| ImagionBiosystems.com
MagSense® Use Cases
9
Detection of Nodal Metastases in
HER2+ Breast Cancer
Primary Tumor Detection
in Prostate Cancer
Following primary tumor diagnosis determine if
the cancer has spread to
the lymph nodes.
Following elevated PSA blood test, the
MagSense® PSMA test would identify if there
is a prostate tumor.
Improves on existing standard-of-care
(ultrasound) which is limited to a small number
of nodes and to assessment for abnormal
size/shape only.
Reduces biopsies to only those who test
positive by MagSense® PSMA.
Reduces the need for biopsy and
provides additional context for treatment and
surgical planning.
Augments biopsy procedure by improving
MRI-guided biopsy.
IBX Investor Deck
Avoids use of radiotracer (PET) testing for
primary diagnosis.
Early Detection of Ovarian Cancer
Following primary tumor diagnosis determine if
the cancer has spread to
the lymph nodes.
Improves on existing standard-of-care (ultrasound)
which is limited to a small number of nodes and to
assessment for abnormal size/shape only.
Reduces the need for biopsy and
provides additional context for treatment and
surgical planning.
Copyright August 2024
| ImagionBiosystems.com
Clinical Study – IBI010103
Detection of Nodal Metastases in HER2+ Breast Cancer
• A Phase 1 Study with 13 HER2+ Breast Cancer patients
from 4 sites in Australia.
• Imaging agent was safe and well tolerated in all 13 patients
with no AE/SAEs reported related to the imaging agent.
• Blinded review by independent expert panel of radiologists
has corroborated detectable magnetic signature.
• Can improve on ultrasound which is limited to assessment for
abnormal size/shape and could reduce need for SLNB/ALND.
• Plans for an IND and multisite Phase 2 study in process.
10
IBX Investor Deck
Copyright August 2024
| ImagionBiosystems.com
Improving Radiological Review
• Radiological assessment is often
subjective, with significant inter-operator
differences in interpretation.
Post-Contrast
• Development of automated software solutions
will allow reliable, automated detection for
easier, accurate reads.
• Using common post-processing techniques,
such as subtraction, only areas with MagSense®
particles remain in the image.
• Machine Learning can be applied to create SaaMD
automated detection solutions.
11
IBX Investor Deck
Pre-Contrast
Post-Contrast
Subtraction
Copyright August 2024
| ImagionBiosystems.com
Rationale for MRI Imaging Agents
Expanding access, Improving outcomes
1. There are >50,000 MRI scanners available globally
(5x as many as PET imaging systems).
2. MagSense® imaging agents have long shelf life and can be
stored and supplied by the hospital pharmacy without the costs
and constraints like radiotracers.
3. Biopsies are expensive and invasive. PET imaging uses radioactivity, and
conventional MRI contrast agents (Gadolinium) are non-specific
and not typically used in cancer detection.
4. The health economics of using MagSense® mMRI are favorable because it fits
within the existing clinical workflow, adds value to the radiologist’s role in
patient management and eliminates unnecessary and costly invasive
procedures, such as biopsies.
12
IBX Investor Deck
Copyright August 2024
| ImagionBiosystems.com
Investor Rationale
13
IBX Investor Deck
Copyright August 2024
| ImagionBiosystems.com
Path to Growth and Value
$3-4B Market
Opportunity
Clinical Development Plan and Key Milestones
Completed
2024 - 2025
IND
HER2+
Breast
Cancer
Phase 2
Phase 1
Phase 3
Dose and Image Protocol Optimization
Nodal Testing and
Surveillance
$200M+/yr
IND
Ovarian
Cancer
Pre-Clinical
IND-enabling
Phase 1
Phase 2
Human Safety
Primary Diagnosis and
Surveillance
$1B/yr
IND
Prostate
Cancer
Pre-Clinical
IND-enabling
Phase 1
Phase 2
Primary Diagnosis
$2B/yr
Copyright August 2024
| ImagionBiosystems.com
Human Safety
* 3 MagSense® Imaging Agents in Clinical Testing
14
IBX Investor Deck
Focus on Strategic Partnering
Sources: (1) JAMA Oncology. 2022.
Medicare Payment Advisory Commission
(MedPAC) and Centers for Medicare and
Medicaid Services (CMS). Mordor
Intelligence. Global Contrast Media
Market
1. Use of contrast media is well established across medical
imaging technologies with molecular imaging being most
dynamic and driving growth.
2. Global cancer incidence continues to rise1 with Screening & Diagnostic
Imaging being one of the fastest growing
healthcare spend sectors as service providers seek ways to
improve determining malignant vs. benign.2
3. MagSense® imaging agents are completely differentiated and fit the existing
medical imaging and contrast media business model.
4. Incumbents continue making attractive deals for
differentiated clinical-stage assets.
• 2024 Hologic acquired Endomagnetics for $300M
15
IBX Investor Deck
Copyright August 2024
| ImagionBiosystems.com
Comparable Transactions
Acquirer
16
IBX Investor Deck
Target
Value AUD
Year
Notes
$18M
2024
Strategic investment. Part of $70M AUD
financing transaction.
$310M
2024
$35M revenue at time of transaction.
Breast cancer
$1.6B
2018
Imuno-oncology agent. Acquired
following successful Phase 3.
$328M Est.
2019
All stock acquisition. Estimated market
cap at transaction date.
$3.9B
2018
Acquired in Phase 3, pending FDA
clearance. Radioligand therapy.
Copyright August 2024
| ImagionBiosystems.com
Imagion 2.0
Restructured Operations and Leadership
Robert Proulx
Ward Detwiler
Melanie Leydin CA FGIA
Brett Mitchell
Executive Chairman
Chief Business Officer
Company Secretary & Non-Executive
Director
Non-Executive Director
Robert is an operationally oriented
executive with over 30 years in life science
& medical device product development &
commercialization and has led the
company through recent restructuring and
recapitalization.
Experienced early stage
technology executive with a
track record of bringing
health technologies from
concept to market.
Melanie is a Chartered Accountant
and a Fellow of the Governance Institute
of Australia with over 30 years of experience
in Accounting and over 20 years in Board
positions, currently the Managing Director
of Vistra Australia.
Mr. Mitchell is an experienced corporate
finance executive with over 25 years
of experience in the venture capital and
equity capital markets, leading transactions
in the mining, energy, technology and life
sciences sectors.
17
IBX Investor Deck
Copyright August 2024
| ImagionBiosystems.com
Imagion 2.0
Key Clinical Milestone
Achieved
• Phase 1 study in 13
HER2+ breast cancer
patients completed
• Safety and tolerability
endpoints achieved
• Independent radiological
review corroborates clinical
utility for nodal detection
18
IBX Investor Deck
Investor Summary
Strong
Pipeline
•
•
Significantly reduced
operating costs
MagSense® HER2 being
readied for IND application
for Phase 2 study to optimize
dose and imaging protocols.
• Eliminated costs of R&D and Manufacturing obligations in
favor of outsourcing to CROs and CMOs.
MagSense® imaging agents
for prostate cancer and
ovarian cancer ready for INDenabling studies.
• Operating as a “virtual” entity.
• Reduced Management and Board to
essentials to maintain compliance.
• Will fund R&D on a “pay-as-you-go” basis keeping spending in
line with secured funding
• Cash burn reduced to <$100K / mos. excluding funding R&D.
Copyright August 2024
| ImagionBiosystems.com
info@imagionbio.com | ASX:IBX
19
IBX Investor Deck
Copyright August 2024
| ImagionBiosystems.com
Share your feedback
Discover